Abstract
We report the first case of profound "pseudohypocalcemia" after the administration of the gadolinium-based contrast media dimeglumine gadopentate (Magnevist; Schering Diagnostics AG, Berlin, Germany) to a long-standing hemodialysis patient. Initial calcium measurements were made by using our routine laboratory colorimetric method based on o-Cresolphthalein (Roche Modular-P; Roche Diagnostics Ltd, Lewes, Sussex, UK). Because the patient was well, with no signs of hypocalcemia, retrospective testing using both another o-Cresolphthalein colorimetric method (Roche Integra 800) and measurement of ionized calcium with an ion-selective electrode were performed, and confirmed laboratory pseudohypocalcemia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
